Clinical Trial

Open Label Extension Study of Brentuximab Vedotin in Early dcSSc

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 18, 2024 (before its estimated February 14, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to assess safety and efficacy of Brentuximab vedotin, a CD30-directed antibody-drug conjugate, in patients with active diffuse cutaneous systemic sclerosis (dcSSc) who relapsed after discontinuation of Brentuximab vedotin.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-11-24; most recent amendment 2024-11-14.
Status change: Not Yet Recruiting → Recruiting 2024-02-23
Trial Details
NCT Number NCT05149768
Lead Sponsor London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Collaborators: Seattle Genetics (now a wholly owned subsidiary of Pfizer), Pfizer
Conditions Diffuse Cutaneous Systemic Sclerosis
Enrollment 11 participants
Start Date 2024-02-14
Primary Completion 2026-02-14 (estimated)
Study Completion 2026-07-01 (estimated)
Updated on ClinicalTrials.gov 2024-11-18